Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus by Yeow, Toh Peng et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin
effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus
Yeow, Toh Peng; Pacini, Giovanni; Tura, Andrea; Hor, Chee Peng; Lim, Shueh Lin; Tan,
Florence Hui Sieng; Tong, Chin Voon; Hong, Janet Yeow Hua; Md Zain, Fuziah; Holst, Jens
Juul; Wan Mohamud, Wan Nazaimoon
Published in:
BMJ open diabetes research & care
DOI:
10.1136/bmjdrc-2016-000352
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Yeow, T. P., Pacini, G., Tura, A., Hor, C. P., Lim, S. L., Tan, F. H. S., ... Wan Mohamud, W. N. (2017).
Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and
sensitivity in young Asians with type 2 diabetes mellitus. BMJ open diabetes research & care, 5(1), [e000352].
https://doi.org/10.1136/bmjdrc-2016-000352
Download date: 03. Feb. 2020
Preserved glucagon-like peptide-1
responses to oral glucose, but reduced
incretin effect, insulin secretion
and sensitivity in young Asians
with type 2 diabetes mellitus
Toh Peng Yeow,1,2 Giovanni Pacini,3 Andrea Tura,3 Chee Peng Hor,4,5
Shueh Lin Lim,2 Florence Hui Sieng Tan,6 Chin Voon Tong,2
Janet Yeow Hua Hong,7 Fuziah Md Zain,7 Jens Juul Holst,8
Wan Nazaimoon Wan Mohamud9
To cite: Yeow TP, Pacini G,
Tura A, et al. Preserved
glucagon-like peptide-1
responses to oral glucose,
but reduced incretin effect,
insulin secretion
and sensitivity in young
Asians with type 2 diabetes
mellitus. BMJ Open Diabetes
Research and Care 2017;5:
e000352. doi:10.1136/
bmjdrc-2016-000352
This study has been
presented at (1) General
Poster Session and
Moderated Poster Discussion
at the American Diabetes
Association’s 76th Scientific
Sessions, June 10–14, 2016,
in New Orleans, Louisiana,
and (2) Young Investigator
Award at the Diabetes Asia
Conference, October 6–9,
2016 in Kuala Lumpur,
Malaysia.
Received 30 October 2016
Revised 31 December 2016
Accepted 24 January 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Toh Peng Yeow; tohpeng.
yeow@pmc.edu.my
ABSTRACT
Objective: Youth onset type 2 diabetes mellitus
(YT2DM) is a globally rising phenomenon with
substantial Asians representation. The understanding of
its pathophysiology is derived largely from studies in
the obese African-American and Caucasian
populations, while studies on incretin effect are scarce.
We examined the insulin resistance, β-cell function
(BC), glucagon-like peptide (GLP)-1 hormone and
incretin effect in Asian YT2DM.
Research design and methods: This case–control
study recruited 25 Asian YT2DM and 15 healthy
controls, matched for gender, ethnicity and body mass
index. Serum glucose, insulin, C peptide and GLP-1
were sampled during 2-hour oral glucose tolerance
tests (OGTTs) and 1-hour intravenous glucose
tolerance tests (IVGTTs). Insulin sensitivity was derived
from the Quantitative Insulin Sensitivity Check Index
(QUICKI), Oral Glucose Insulin Sensitivity Index (OGIS)
in OGTT and surrogate index of SI from the minimal
model (calculated SI, CSI). Acute insulin response
(AIR) was obtained from IVGTT. Total BC was
computed as incremental area under the curve of
insulin/incremental area under the curve of glucose,
during OGTT (BCOG) and IVGTT (BCIV), respectively.
Disposition index (DI) was calculated using the product
of insulin sensitivity and insulin secretion. GLP-1
response to oral glucose was calculated as incremental
area under the curve of GLP-1 (ΔAUCGLP-1). Per cent
incretin effect was estimated as 100×(BCOG−BCIV)/
BCOG).
Results: The YT2DM had marked impairment in BC
(>80% reduction in AIR and BCOG, p<0.001) and lower
QUICKI (p<0.001), OGIS (p<0.001) and CSI (p=0.015)
compared with controls. There was no difference in
GLP-1 at all time points and ΔAUCGLP-1 but the per
cent incretin effect was reduced in the YT2DM
compared with controls (12.1±8.93 vs 70.0±4.03,
p<0.001).
Conclusions: Asian YT2DM showed similar GLP-1
response to oral glucose as controls but reduced
incretin effect, BC and insulin sensitivity. The lack of
compensatory mechanisms, as shown by the DI may
be partly ascribed to the impaired incretin effect,
similar to that of adult T2DM.
Trial registration number: NMRR-12-1042-13254.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) among the
youth is a rising phenomenon which poses a
public health challenge because develop-
ment and progression of clinical complica-
tions may be more rapid, and associated with
greater mortality when the onset of T2DM is
early.1 2 In the USA, up to 45% of diabetes
in adolescents cases are now being attributed
to T2DM.3 Adolescents of Asian descent are
major contributors of pediatric T2DM.4 5
Studies suggest that impaired glucose toler-
ance and T2DM in obese youth is due to a
Significance of this study
What is already known about this subject?
▪ Youth onset type 2 diabetes mellitus (YT2DM) is
characterised by obesity, insulin resistance and
β-cell impairment.
What are the new findings?
▪ In this study, the Asian YT2DM have preserved
glucagon-like peptide (GLP)-1 response to oral
glucose but decreased incretin effect, β-cell func-
tion and insulin sensitivity.
How might these results change the focus of
research or clinical practice?
▪ Further clinical studies in YT2DM are needed to
establish the possibility of ‘GLP-1 resistance’ and
if incretin-based therapy can benefit glycemic
control in YT2DM.
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combination of progressive and rapid deterioration of
β-cell function (BC) in the presence of insulin resist-
ance.6 7 However, the degree of insulin resistance and
the ability of the β-cell to secrete sufﬁcient insulin to
adequately respond to the peripheral insulin resistance
state appear to vary among different populations and
appear to be inﬂuenced by genetic and environmental
factors.1 8 Most studies on youth onset T2DM (YT2DM)
were conducted on African-American and Caucasian
obese subjects.9–11 Pathophysiological characterization
studies among the Asians and studies on incretin effect
among youth with T2DM are limited.
The aim of our study was the characterization of a
multiethnic Asian population of youth with T2DM and
control subjects with comparable gender, ethnicity and
body mass index (BMI). We accomplished this character-
ization by (1) examining insulin resistance and BC both
from oral and intravenous glucose tolerance tests
(IVGTT); (2) assessing the incretin hormone (glucagon-
like peptide-1, GLP-1) response during the oral test; and
(3) estimating the ‘incretin effect’ by relating the differ-
ences in β-cell responses, from insulin and C peptide,
between stimulation with oral and intravenous glucose.
RESEARCH DESIGN AND METHODS
Subjects with diabetes were recruited from the specialist
clinics of three referral hospitals in Malaysia (Penang,
Putrajaya and Sarawak General Hospitals). They had
been diagnosed and managed as T2DM based on the
WHO criteria12 with either clinical features of insulin
resistance or long clinical course of non-insulin depend-
ency (ie, absence of diabetic ketoacidosis despite
defaulting from insulin therapy). Controls without dia-
betes and without blood relation, matched for gender,
ethnicity and BMI were recruited from community via
word of mouth. All participants were <25 years old at the
time of assessment.
The participants attended the clinical research centers
on three different occasions within a 40-day period to
undergo baseline assessment, CT scan for abdominal
subcutaneous and visceral fat quantiﬁcation, oral
glucose tolerance test (OGTT) and IVGTT. All subjects
underwent similar evaluation.
The study was registered at the Malaysian National
Medical Research Register (NMRR 12-1042-13254) on
November 29, 2012. The Malaysian Medical Research
and Ethics Committee approved the study on June 28,
2013. Written informed consents were obtained from all
participants. For participants younger than 18 years old,
assent were obtained using a separate age appropriate
assent form, alongside written consent from the minor’s
parents(s) or guardian(s).
Baseline history, anthropometric measurement and
laboratory assessment
Baseline information included age, ethnicity, birth
history and family history of diabetes, age of diagnosis,
duration of diabetes and use of oral antidiabetic agents
(OADs) were obtained during baseline assessment.
Weight, height, BMI, waist and hip circumferences,
blood pressure, presence of acanthosis nigricans and
Tanner staging were documented from physical examin-
ation. Microalbuminuria was deﬁned as microalbumin-
creatinine ratio of >2.5 mg/mmol for men and >3.5 mg/
mmol for women on at least two separate occasions.
Fasting venous blood samples (after an overnight fast
of 10 hours) were drawn for plasma glucose, lipid
proﬁle, glycated hemoglobin (HbA1c), renal proﬁle,
liver function tests, glutamic acid decarboxylase-65
antibody (GAD65 Ab) and Islet antigen-2 antibody
(IA2 Ab).
Abdominal fat quantification
Limited axial CT scan of the abdomen was performed at
L4–L5 intervertebral level. The area of abdominal
adipose tissue was calculated using OsiriX imaging soft-
ware. Tissue with Hounsﬁeld unit between −30 and
−190 was considered as adipose tissue. Abdominal adi-
posity was quantiﬁed as total, subcutaneous and visceral
adipose tissues.
OGTT and IVGTT
Each subject underwent OGTT and IVGTT on two separ-
ate occasions, 24–48 hours apart. For female subjects,
these tests were performed during the follicular phase
of menstrual cycle. On both occasions, the subjects were
studied in a recumbent position after overnight
(10 hours) fasting, restraining from medication and
tobacco use. For the subjects with diabetes on OADs,
the medications were stopped for a minimum of 5 days
before any test. Short or intermediate acting insulin was
started in the interim to maintain glycemic control, at
the discretion of the attending endocrinologists.
Subjects regularly treated with long-acting insulin were
temporarily changed to short or intermediate acting
insulin the night before the tests. The last dose of
insulin was given at least 12 hours before the tests to
avoid interference with the measurements. Subjects on
OADs restarted their usual medications after completion
of OGTT and IVGTT.
OGTT—Glucose, insulin and C peptide were sampled
at time 0, 30, 60, 90, 120 min after a glucose load
(1.75 g/kg, maximum 75 g). GLP-1 hormone was
sampled at time 0, 15, 30, 60 and 90 min after the
glucose load.
IVGTT—A cannula was inserted in an antecubital vein
for blood sampling. Basal blood for measurement of
glucose, insulin and C peptide were collected at time
−10 and −1 min, after which glucose (300 mg/kg body
weight) was infused into a contralateral vein within 30 s,
starting at time 0. Blood was then sampled for glucose,
insulin and C peptide at time 3, 5, 6, 8, 10, 15, 20, 25,
30, 40, 50 and 60 min postbolus glucose.13
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Biochemical measurement
Serum insulin and C peptide were measured on
TOSOH ALA System Analyzer using two-site immunoen-
zymometric assay kits (ST AIA-PACK IRI and ST
AIA-PACK C peptide II, respectively) supplied by
TOSOH Corporation, Shiba-koen First Bldg., 3-8-2
Shiba, Minato-ku, Tokyo 105-8623 Japan. Interassay coef-
ﬁcient of variation (CV) for insulin at 62 and 146 μU/
mL were 8.8% and 4.9%, respectively, and for C peptide
at 2.0 and 18.1 ng/mL were 8.3% and 7.9%, respectively.
The insulin and C peptide measurements were changed
to SI units for subsequent computation and reporting.
Both GAD65 Ab and IA2 Ab were measured using
solid phase enzyme immunoassay (IBL International
GMBH). The intra-assay (n=5) CVs for GAD65 Ab calcu-
lated at 16.9 and 64.94 IU/mL were 7.6% and 8.3%,
respectively, while the corresponding interassay (n=5)
CVs were 8.4% and 13.8%, respectively. The intra-assay
(n=5) CVs for IA2 Ab calculated at 8.68 and 54.02 IU/
mL were 15.7% and 9.8%, respectively, while the corre-
sponding interassay (n=5) CVs were 18.6% and 13.7%,
respectively. GAD65 Ab and/or IA2 Ab of > 30 IU/mL
are considered positive.
Blood samples for GLP-1 measurement were taken in
EDTA tubes and put on ice immediately, centrifuged for
plasma content and stored at −80°C. GLP-1 concentra-
tions in plasma were measured by radioimmunoassays
after extraction of plasma with 70% ethanol (vol/vol,
ﬁnal concentration). Carboxyterminal GLP-1 immunor-
eactivity was determined using antiserum 89390 which
has an absolute requirement for the intact amidated car-
boxyterminus of GLP-1 7-36amide and cross reacts
<0.01% with carboxyterminally truncated fragments and
89% with GLP-1 9-36amide, the primary metabolite of
dipeptidyl peptidase IV-mediated degradation. The sum
of the two components (total GLP-1 concentration)
reﬂects the rate of secretion of the L cell. Sensitivity was
below 1 pmol/L and intra-assay CV was <5%.14
Insulin sensitivity and BC
From the OGTT, fasting and peripheral (dynamic)
insulin sensitivities were determined by the Quantitative
Insulin Sensitivity Check Index (QUICKI) and the Oral
Glucose Insulin Sensitivity Index (OGIS), respectively.
These indices have been validated against clamp in
T2DM.15 From the IVGTT, insulin sensitivity was esti-
mated with calculated SI (CSI), a validated surrogate
index of insulin sensitivity index from the minimal
model (SI).16
Homeostatic model assessment for BC (HOMA-%B)
was used as a measure of fasting β-cell activity.15 17 Insulin
secretion was evaluated with the area under the curve
(AUC), calculated using the trapezoidal method. During
the OGTT, insulin secretion was evaluated with the AUC
of C peptide (AUCc peptide) and the amount of insulin
reaching the periphery (posthepatic) with AUC of
insulin (AUCinsulin). Early phase insulin response during
OGTT was calculated for the ﬁrst 30 min using
insulinogenic index, IGI=ΔI30/ΔG30=(I30−Ibasal)/
(G30−Gbasal), while the corresponding index for
C peptide, IGIC peptide was ΔCP30/ΔG30=(CP30−CPbasal)/
(G30−Gbasal). Acute insulin response (AIR) during
IVGTT was calculated from the suprabasal average of
insulin in the 3–10 min interval after the glucose bolus.
The BC describes the ability of glucose to stimulate
insulin release from β-cells. It was calculated as incremen-
tal AUCinsulin (ΔAUCinsulin) and AUCc peptide (ΔAUCc
peptide) over the incremental AUCglucose (ΔAUCglucose) in
both tests, which are BCOG during OGTT and BCIV
during IVGTT.18 We also calculated the shape index
(Whole-Ogtt-Shape-index, WHOSH) for glucose, insulin
and C peptide, which correlate with a model-based
parameter of BC. Shape indices quantify the degree of
variation of a curve. Previous study has shown that a
complex shape (ie, higher variability) is associated with
better glucose tolerance condition. The C peptide shape
index (WHOSHC peptide) has also been shown to correl-
ate with a model-based parameter of BC.19
BC cannot be correctly assessed unless adjusted for
the prevailing insulin resistance.20 Under normal condi-
tions, a balance between insulin secretion and insulin
sensitivity maintains the tight glucose regulation. The
disposition index (DI) reﬂects the ability to maintain
glucose regulation through a balance between insulin
secretion and insulin sensitivity. DI was calculated using
the product of insulin sensitivity and insulin secretion
from OGTT using product of OGIS×ΔAUCinsulin and
from IVGTT using product of CSI×AIR.
Assessment of incretin hormone secretion and incretin
effect
The incretin hormone, GLP-1, was measured during the
2-hour OGTT at times 0, 15, 30, 60 and 90 min. The
GLP-1 secretion was presented as total AUC (tAUC) cal-
culated using the trapezoidal method. The relative
response was calculated as fold increase of GLP-1 relative
to baseline. Relative early response of GLP-1 (GLP
rAUC0–15) was calculated as tAUC0–15/(fasting
concentration×15 min) and the relative full response
(GLP rAUC0–90) was calculated as tAUC0–90/(fasting
concentration×90 min). The incretin effect was esti-
mated by relating the differences in β-cell responses
from C peptide between stimulation with oral and intra-
venous glucose. The incretin effect was estimated by the
formula 100×(BCOG−BCIV)/BCOG.21
Statistical analyses
With a ratio of YT2DM to control subjects of 2:1, a
sample size of 28 T2DM and 14 control subjects would
have the 80% power to detect a mean difference of
70 mL/min/m2 in OGIS (eg, difference between T2DM
mean of 350 ml/min/m2 and control’s mean of
420 mL/min/m2), with the common SD of 75, and
p<0.05.22 Besides, based on a previous study by Pacini
et al,21 assuming 66±25% is the incretin effect in 35 con-
trols, 31 T2DM subjects were sufﬁcient to detect a mean
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difference of 48±25% incretin effect, with 80% power
and p<0.05.
The data were collected and analyzed using Statistical
Package for the Social Sciences (SPSS) V.20.0. The data
were de-identiﬁed before their use in analyses. Data of
categorical variables were presented in n (%). Data of
continuous variables were described in mean±SEM.
Inferential analyses using χ2 test were performed
between T2DM and control subject groups for demo-
graphics, clinical history, metabolic control, and develop-
ment of comorbidities and complications. Fisher’s exact
tests were employed wherever assumptions for χ2 tests
were not fulﬁlled. Independent Student’s t-tests were
employed to investigate the mean differences between
T2DM and control groups for age, glycemic and meta-
bolic parameters, indices for insulin sensitivity, BC and
incretin effect. The relationship between glycemic
control (HbA1c) and incretin effect was examined by
Pearson’s correlation.
RESULTS
Study subjects
Thirty subjects with clinical diagnosis of T2DM and 18
controls matched for gender, ethnicity and BMI were
recruited for this study. Five youth with diabetes and
three controls were excluded due to positive pancreatic
autoantibodies. Subsequent comparisons were made
between the 25 youth with antibodies negative T2DM
(YT2DM) and 15 matched controls. The YT2DM were
on variable treatment regimens that include diet therapy
alone (n=2), metformin alone (n=11), dual OADs (n=4)
and combination of OAD(s) and insulin (n=8). The
HbA1c was 10.0±4.0% (86±43 mmol/mol) with diet
therapy alone, 7.7±1.6% (61±18 mmol/mol) with met-
formin alone, 9.0±0.5% (75±6 mmol/mol) with dual
OADs and 8.5±2.0% (69±21 mmol/mol) with OAD(s)
and insulin (p=0.336).
Table 1 summarizes subjects’ characteristics and
fasting metabolic proﬁle. There were no signiﬁcant dif-
ferences in gender, ethnic distributions and pubertal
staging but the YT2DM group was about 4 years younger
than the controls. The YT2DM group was twice as likely
to have either/or both parents with T2DM. Acanthosis
nigricans, a marker of insulin resistance, was three times
more likely in the YT2DM group. The YT2DM had
greater visceral adiposity, despite similar total and sub-
cutaneous adiposity compared with controls.
Glucose, insulin and C peptide responses during OGTT
Figure 1A–C illustrates the glucose, insulin and C
peptide excursion during OGTT. Glucose was higher at
every time point in the YT2DM than controls. Fasting
insulin and C peptide were higher in the YT2DM at
baseline. The total pancreatic insulin secretion over
2 hours during the OGTT, as measured by AUCC peptide
were lower in the YT2DM compared with controls, 1630
±207.3 vs 2796±217.8 (×102) min×pmol/L (p=0.001).
The total insulin reaching the peripheral circulation, as
measured by AUCinsulin were similarly lower in the
Table 1 Physical characteristics and fasting metabolic profile
YT2DM (n=25) Control (n=15) p Value
Age, range (years) 18.5±0.92, (11–25) 22.0±0.85, (13–24) 0.008
Male:female 12:13 7:8 0.935
Ethnicity—Malay:Chinese:others 16:6:3 12:2:1 –*
BMI (kg/m2) 30.2±1.05 27.3±1.08 0.081
Age at diagnosis of diabetes (years) 16.1±0.92 – –
Duration of diabetes (months) 23.1±6.42 – –
Family history of diabetes (including first-degree
and second-degree relatives)
24 (96.0) 12 (80.0) 0.139†
Tanner stages
II–III 3 (12.0) 0 0.279†
IV–V 22 (88.0) 15 (100.0)
Acanthosis nigricans 18 (72.0) 3 (20.0) 0.001
Fasting blood glucose (mmol/L) 9.9±0.85 4.5±0.06 <0.001
HbA1c (%) 8.4±0.37 5.3±0.09 <0.001
HbA1c (mmol/mol) 68±4 34±1 <0.001
Microalbuminuria 14 (56.0) 0 <0.001
Systolic BP (mm Hg) 120.8±2.31 116.1±2.72 0.200
Diastolic BP (mm Hg) 73.8±2.00 69.5±2.22 0.173
Waist:hip ratio 0.9±0.01 0.8±0.02 0.011
Total adipose tissue (cm2) 421±31.0 364±47.0 0.297
Visceral adipose tissue (cm2) 79±7.6 53±8.5 0.035
Subcutaneous adipose tissue (cm2) 339±25.9 302±41.0 0.433
*Inferential analysis was not performed for this variable as assumptions for both χ2 and Fisher’s exact tests were not fulfilled.
†Fisher’s exact test.
BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin.
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YT2DM, 3453±647.3 vs 6240±748.4 (×101) min×pmol/L
(p=0.009).
Insulin sensitivity and BC
The indices generated from OGTT and IVGTT are
reported in table 2 and ﬁgure 2A–C. The YT2DM had
lower fasting insulin sensitivity (QUICKI) and peripheral
insulin sensitivity (OGIS) than the controls. The
IVGTT-derived CSI was also lower in the YT2DM group.
The early phase insulin responses to glucose challenge,
as measured by AIR, were diminished by more than 80%
when compared with the controls. IGI and IGIC peptide
were similarly lower though they did not reach statistical
signiﬁcance. The BC, BCOG−insulin and BCIV−insulin were
reduced in the YT2DM group by 86% and 62%, respect-
ively. The reduced BC was further conﬁrmed by the
lower WHOSHC peptide in the YT2DM. The DI, both
derived from OGTT and IVGTT, was also reduced in the
YT2DM subjects.
Incretin hormone secretion and incretin effect
The GLP-1 responses during OGTT are shown in
ﬁgure 1D. There was no difference in GLP-1 secretion at
baseline and all subsequent time points between
YT2DM and control subjects. The total GLP-s secretion
(tAUC0–90) for YT2DM and control groups were
1223.4±79.40 and 1347.5±125.84 pmol/L, respectively
(p=0.385). Early phase and total GLP-1 secretion were
otherwise similar between groups both in absolute
(tAUC) and relative (rAUC) terms. Despite the similar
level of GLP-1 secretion, incretin effect was signiﬁcantly
reduced in the YT2DM group (12.1±8.93% vs 70.0
±4.03%, p<0.001; ﬁgure 2D). The incretin effect was
inversely correlated with HbA1c in our study (r2=0.271,
p<0.001).
DISCUSSION
T2DM in the youth from a multiethnic Malaysian popu-
lation, when compared with peers with normal glucose
tolerance, is characterized by decreased insulin sensitiv-
ity and relative impairment in BC. In the fasting state,
insulin sensitivity (QUICKI) and BC (HOMA-%B) were
markedly lower in YT2DM, reﬂecting hepatic insulin
resistance23 and impaired β-cell activity, respectively.
Majority of our participants (88% of YT2DM and 100%
controls) had Tanner stage IV and V. The effect of
puberty on the difference observed in insulin sensitivity
is therefore minimal. Decreased insulin sensitivity and
BC are also observed in studies among Korean,
Taiwanese and Indian youth with T2DM.24–26
Figure 1 Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among
subjects with normal glucose tolerance (NGT) (circles with solid line) and YT2DM (squares with dotted line). Data were presented in
mean±SEM. GLP-1, glucagon-like peptide-1; OGTT, oral glucose tolerance test; YT2DM, youth onset type 2 diabetes mellitus.
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Obesity is considered one of the major triggers for
YT2DM, with inadequate insulin secretion to compen-
sate for the rising insulin resistance driven by obesity
and puberty.3 The Asian YT2DM in our study have lower
mean BMI than the African-American and Caucasian
adolescents with T2DM reported in previous
studies8 9 27 28 but similar insulin sensitivity (OGIS).8
About 50% of the Taiwanese youth with T2DM had
BMI<27 kg/m2 and insulin sensitivity were similar in the
obese and non-obese YT2DM.25
In our study, the reduction in BC derived during
OGTT (BCOG) in YT2DM was more pronounced than
the reduction in insulin sensitivity (OGIS), suggesting
that β-cell dysfunction plays a more important role in
reducing glucose tolerance. There was also impaired
ability of the β-cell to adjust for the prevailing insulin
resistance, as evidenced by reduced DI. These observa-
tions were consistent with previous studies which demon-
strated greater impairment in BC relative to insulin
sensitivity in youth with T2DM.25 26 29
Our result adds to the scarce literature in youth with
T2DM by providing novel information on the incretin
effect and GLP-1 concentrations during the OGTT. We
demonstrated that YT2DM have similar GLP-1 concentra-
tion in response to the oral glucose compared with
control subjects with normal glucose tolerance. This is
consistent with ﬁndings from two meta-analyses in adults
with T2DM30 31 despite earlier contrasting reports in
smaller studies.32 33 The ADDITION-PRO study, based
on a population of screen-detected diabetes also demon-
strated reduced GLP-1, especially late GLP-1 responses at
120 min, during an OGTT in screen-detected T2DM.34
We did not capture GLP-1 level at 120 min. However,
studies showed that GLP-1 level generally peak at 30 min
and reach a plateau by 90 min after oral glucose chal-
lenge.10 24 35 It may be safe to assume that GLP-1 level at
90 min is similar to that at 120 min. The discrepancy may
reﬂect the different population studied since GLP-1
secretion has been shown to be affected by diabetes dur-
ation, severity of diabetes, age, sex and BMI.34 Our
YT2DM were younger, with short duration of diabetes
but signiﬁcant degree of hyperglycemia. The majority of
our YT2DM were on metformin which has been demon-
strated to increase GLP-1 secretion.36 The ‘good’ level of
GLP-1 secretion may also be due to the residual effect of
metformin even though our subjects had their medica-
tions stopped for a minimum of 5 days prior to the
OGTT. Korean children and adolescents with T2DM who
were treatment naive were also found to have preserved
intact GLP-1 secretion when assessed during OGTT.24
Despite the similar GLP-1 secretion, the incretin effect
was reduced by more than 80% in our YT2DM com-
pared with controls. Lesser degree of reduction in incre-
tin effect has also been observed in two other studies
Table 2 OGTT-modeled and IVGTT-modeled parameters of insulin sensitivity and β-cell function
YT2DM (n=25) Control (n=15) p Value
OGTT-modeled parameters
Insulin sensitivity
QUICKI 0.21±0.006 0.27±0.010 <0.001
OGIS (mL/min/m2) 281.8±16.54 421.3±16.46 <0.001
β-cell function
HOMA-%B 110.9±26.88 230.9±42.10 0.016
IGI (pmol/mmol) 32.5±13.39 378.4±181.53 0.080
IGIC peptide (pmol/mmol) 97.4±27.85 1584.2±985.26 0.155
BCOG−insulin (pmol/mmol)] 34.1±11.25 244.3±41.57 <0.001
BCOG−C peptide (pmol/mmol)] 2978±772.0 15 267 ±2542.2 <0.001
Shape indices
WHOSHglucose (×10
−3) (min–2×mmol/L) 3.2±0.50 2.0±0.20 0.079
WHOSHinsulin (×10
−2) (min–2×μU/mL) 2.8±0.60 7.0±1.33 0.008
WHOSHC peptide (×10
−3) (min–2×ng/mL*) 1.3±0.28 3.4±0.60 0.004
DI
DI (mL/min/m2)×(min×pmol/L)] (×108) 600.6±164.33 2239.6±228.58 <0.001
IVGTT-modeled parameters
Insulin sensitivity
CSI (×10–4) ((min–1)×(μU/mL)–1] 1.7±0.24 4.0±0.81 0.015
β-cell function
AIR (pmol/L) 73.5±25.49 487.5±64.49 <0.001
BCIV−insulin (pmol/mmol)] 19.8±5.93 51.5±8.06 0.003
BCIV−C peptide(pmol/mmol)] 2297.3±422.48 3556.2±495.28 0.065
DI
DI [(mL/min/m2)×(min×pmol/L)] (×104) 60.8±13.18 1939.7±617.60 0.009
AIR, acute insulin response; BC, β-cell function; CSI, calculated SI; DI, disposition index; HOMA-%B, homeostatic model assessment for BC;
IGI, insulinogenic index; IVGTT, intravenous glucose tolerance test; OGIS, Oral Glucose Insulin Sensitivity Index; OGTT, oral glucose
tolerance test; YT2DM, youth onset type 2 diabetes mellitus; QUICKI, Quantitative Insulin Sensitivity Check Index; WHOSH,
Whole-Ogtt-Shape-index.
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among non-Asian youth with T2DM.10 37 However, the
incretin effect was derived differently from all three
studies making direct comparison inaccurate. The
greater reduction in incretin effect in our study may be
due to the poorer glycemic control among our subjects
since hyperglycemia has been proposed to downregulate
GLP-1 receptor expression on β-cells and cause ‘GLP-1
resistance’.34 We also found a signiﬁcant inverse correl-
ation between HbA1c and incretin effect. The lack of
compensatory mechanisms, as shown by the DI may be
partly ascribed to the impaired incretin effect, observed
without reduction in GLP-1. Further clinical studies in
YT2DM are needed to establish if incretin-based therapy
can beneﬁt glycemic control in YT2DM. The possibility
of ‘GLP-1 resistance’ could also have important implica-
tions for the design of new therapies based on modula-
tions of the GLP-1 pathways.
CONCLUSIONS
The current study adds to the scarce literature in adoles-
cents with T2DM of Asian descent. In this multiethnic
Asian cohort, pathophysiology of YT2DM is character-
ized by marked impaired BC in the presence of insulin
resistance. Incretin effect is impaired in adolescents with
T2DM compared with controls, possibly without reduc-
tion in GLP-1, similar to that seen in adult T2DM. This
understanding can help guide the choice of therapeutic
modalities and is relevant to all physicians in our
increasingly globalized world.
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